

Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/21/2025 | $32.00 | Buy | Canaccord Genuity |
11/27/2024 | $16.00 | Equal-Weight | Morgan Stanley |
11/15/2024 | Peer Perform | Wolfe Research | |
10/17/2024 | Neutral | Guggenheim |
MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to
Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m
MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution.
MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern
Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees
8-K - GRAIL, Inc. (0001699031) (Filer)
S-8 - GRAIL, Inc. (0001699031) (Filer)
10-Q - GRAIL, Inc. (0001699031) (Filer)
Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m
MENLO PARK, Calif., April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business
SC 13G - GRAIL, Inc. (0001699031) (Subject)
SC 13G - GRAIL, Inc. (0001699031) (Subject)
SC 13G/A - GRAIL, Inc. (0001699031) (Subject)
Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00
Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00
Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform
4 - GRAIL, Inc. (0001699031) (Issuer)
4 - GRAIL, Inc. (0001699031) (Issuer)
4 - GRAIL, Inc. (0001699031) (Issuer)